73 results about "Stable angina" patented technology

Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and / or preventing pulmonary arterial hypertension and / or stable angina. More particularly, aspects of the present invention are related to therapeutic combinations comprising a Rho-kinase inhibitor, such as fasudil, and one or more additional compounds selected from the group consisting of prostacyclins, such as iloprost, endothelin receptor antagonists, PDE inhibitors, calcium channel blockers, 5-HT2A antagonists, such as sarpogrelate, selective serotonin reuptake inhibitors, such as fluoxetine, statins, and vascular remodeling modulators, such as Gleevec.

The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and / or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value. In other embodiments, risk of thrombosis in a patient is evaluated in the context of a profile generated from values obtained from one or more assays that evaluate various factors associated with thrombosis and / or atherosclerosis.

Method is provided of treating or preventing hypertrophy, hypertension, myocardial ischemia, ischemic heart disease, myocardial infarction, congestive heart failure, organ ischemia, tissue ischemia, acute coronary syndrome, unstable angina, ischemia reperfusion injury, preventing death subsequent to myocardial infarction, cerebral infarction, contractile dysfunction subsequent to myocardial infarction, or arrhythmia in a mammal with low doses of pyridoxine, pyridoxal-5′phosphate, pyridoxal or pyridoxamine. Compositions and kits for said method is also included.

The present invention relates to methods for the diagnosis and evaluation of acute coronary syndromes. In particular, patient test samples are analyzed for the presence and amount of members of a panel of markers comprising one or more specific markers for myocardial injury and one or more non-specific markers for myocardial injury. A variety of markers are disclosed for assembling a panel of markers for such diagnosis and evaluation. In various aspects, the invention provides methods for the early detection and differentiation of stable angina, unstable angina, and myocardial infarction. Invention methods provide rapid, sensitive and specific assays that can greatly increase the number of patients that can receive beneficial treatment and therapy, reduce the costs associated with incorrect diagnosis, and provide important information about the prognosis of the patient.

The invention relates to a method for treatment of unstable coronary artery disease, which is characterised by an early revascularisation together with administration of a low molecular weight heparin. Preferably the low molecular weight heparin is administered up to revascularisation. The methods are also useful for treatment of unstable angina and not worsening chest pain and for treatment of non-Q-wave myocardial infarction (mild heart attack).

The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and / or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value. In other embodiments, risk of thrombosis in a patient is evaluated in the context of a profile generated from values obtained from one or more assays that evaluate various factors associated with thrombosis and / or atherosclerosis.

The present invention relates to liquid compositions of nimodipine and administration of said compositions. New stable liquid compositions of nimodipine can be used to treat conditions such as, but not limited to, aneurysms, subarachnoid hemorrhage, vasospastic angina, Prenzmetal's angina, stable angina, acute myocardial infarction, myocardial arrest, arrhythmia, systemic hypertension, pulmonary hypertension, congestive heart failure, and hypertrophic cardiomyopathy.

A method having clinically sufficient degree of diagnostic accuracy for detecting the presence of coronary artery disease in a human patient from the general population and for distinguishing between the stages of the disease in that patient is disclosed. The stages are, first, the non-acute stage, which is either asymptomatic coronary artery disease or stable angina, second, the acute stage known as unstable angina, and, third, the acute stage known as acute myocardial infarction. The diseased state (as opposed to the non-diseased state) is indicated by the clinically significant presence of a first marker in a sample from the patient. The presence of one of the two acute stages, unstable angina or acute myocardial infarction, is indicated by the clinically significant presence of a second marker in a sample from the patient. The presence of the more severe acute stage known as acute myocardial infarction is indicated by the clinically significant presence of a third marker in a sample from the patient. Preferably the first marker comprises OxLDL, the second marker comprises MDA-modified LDL, and the third marker is a troponin. Preferably the OxLDL and MDA-modified LDL are detected using monoclonal antibodies that can detect the presence of those markers in undiluted human plasma at concentrations as low as 0.02 milligrams / deciliter.

The invention provides new uses for specific binders to the Al domain of the von Willebrand Factor (vWF), in particular the use in patients with stable angina undergoing elective percutaneous coronary intervention. Furthermore, dosing schedules and use of suitable assays such as RIPA and RICO in the particular disease settings are provided.

The invention discloses a metabolite marker for diagnosing and distinguishing coronary atherosclerosis and stable angina pectoris. The metabolite marker includes one or more of phosphorylcholine, palmitoylethanolamine, phytosphingosine, phosphatidylcholine, ethyl chenodeoxycholic acid, lysophosphatidyl choline (16:0), lysophosphatidyl choline (18:2) and phosphatidyl inositol (20:4 / 0:0). When the single metabolite marker is used for diagnosing and distinguishing a patient suffering from the stable angina pectoris and a patient suffering from the coronary atherosclerosis, the ROC areas under the curve (AUC) are greater than 0.7, and the marker has clinical diagnostic significance. When the markers are combined for diagnosis, the AUC is further improved with the increase of the combination number; when all eight markers are combined, the AUC is the highest and is up to 0.985, and the sensitivity and specificity are 97.4% and 98.0% respectively under the condition of an optimal cutoff value. The metabolite marker can accurately diagnose and distinguish the coronary atherosclerosis and the stable angina pectoris and is high in accuracy and good in sensitivity and specificity.

The present disclosure relates to a method and a diagnostic kit for diagnosing stable angina and acute myocardial infarction early through simple blood testing and checking of clinical parameters. Unlike conventional diagnostic methods, stable angina can be diagnosed as distinguished from acute myocardial infarction according to the present disclosure by using one diagnostic platform based on the change in the in-vivo levels of biological metabolites having different metabolic pathways and clinical parameters as well as medications affecting the onset and progress of the disease through multivariable analysis.

The invention discloses ginkgo leaf pills and a preparation method thereof. The ginkgo leaf pills are prepared from a ginkgo leaf extract, a fiveleaf gynostemma herb extract and a lucid ganoderma extract through reasonable compatibility according to different characteristics of raw materials. The formula of the ginkgo leaf pills is made according to the theory of traditional Chinese medicine and essence is extracted, so that the ginkgo leaf pills can have better effects of reducing blood pressure and blood fat, promoting blood circulation, removing blood stasis and dredging collaterals, and are nontoxic and harmless to human bodies. The ginkgo leaf pills are used for treating chest obstruction, cardiodynia and apoplexia caused by blocked blood and qi, and have good curative effect on coronary disease, stable angina pectoris and cerebral infarction.

A method having clinically sufficient degree of diagnostic accuracy for detecting the presence of coronary artery disease in a human patient from the general population and for distinguishing between the stages of the disease in that patient is disclosed. The stages are, first, the non-acute stage, which is either asymptomatic coronary artery disease or stable angina, second, the acute stage known as unstable angina, and, third, the acute stage known as acute myocardial infarction. The diseased state (as opposed to the non-diseased state) is indicated by the clinically significant presence of a first marker in a sample from the patient. The presence of one of the two acute stages, unstable angina or acute myocardial infarction, is indicated by the clinically significant presence of a second marker in a sample from the patient. The presence of the more severe acute stage known as acute myocardial infarction is indicated by the clinically significant presence of a third marker in a sample from the patient. Preferably the first marker comprises OxLDL, the second marker comprises MDA-modified LDL, and the third marker is a troponin. Preferably the OxLDL and MDA-modified LDL are detected using monoclonal antibodies that can detect the presence of those markers in undiluted human plasma at concentrations as low as 0.02 milligrams / deciliter.

The invention discloses a metabolite marker for diagnosing stable angina pectoris. The metabolite marker comprises one or more of phosphorylcholine, palmitoylethanolamine, lysophosphatidylcholine (16:0), lysophosphatidylcholine (18:2), lysophosphatidylcholine (18:1) and phosphatidylinositol (20:4 / 0:0). When the single metabolite marker is used for diagnosing the stable angina pectoris and distinguishing a patient having the stable angina pectoris from a person with normal arteria coronaria, area under the curve (AUC) of ROC is greater than 0.7, and the metabolite marker has clinical diagnostic significance; and when a plurality of metabolite markers are used for diagnosis in a combination manner, along with increasing of the number of the combined metabolite markers, AUC is increased further, is maximum when the six metabolite markers are combined completely, and reaches 0.988, and under the optimal cutoff value, sensitivity and specificity are 98.3% and 99.2% respectively. The metabolite marker provided by the invention can accurately diagnose the stable angina pectoris, and is high in accuracy, high in sensitivity and high in specificity.

This application discloses a method of differentiating stable angina pectoris from acute coronary syndrome, including: obtaining a blood plasma sample from a patient; measuring a relative concentration of at least one metabolic biomarker in the blood plasma sample, wherein the at least one metabolic biomarker is selected from the group consisting of malic acid, taurine, arachidonic acid, citramalic acid, methionine, and pentadecanoic acid; calculating a value according to the relative concentration of at least one metabolic biomarker; comparing the value with a predefined critical value, if the value is more than the predefined critical value, the patient has the acute coronary syndrome, otherwise, the patient has the stable angina pectoris. The method and a diagnostic kit thereof is capable of differential diagnosis of SA and ACS and it can improve the diagnostic convenience and promote the diagnostic standardization.

The invention discloses a marker group for diagnosing and distinguishing coronary arterial atherosclerosis from stable angina pectoris. The marker group comprises one or more of glutathione, beta-hydroxybutyric acid, proline, fumaric acid, phenylalanine and lactic acid. When a single marker is used for diagnosing and distinguishing patients with the stable angina pectoris from patients with the coronary arterial atherosclerosis, the AUCs (areas under curve) of a ROC (receiver operating characteristic) are all 0.7 or larger, and the marker has a clinical diagnosis significance; when the markers are used for diagnosis in combination, with the increase of the combination number, the AUC is further increased and reaches 0.988 when 6 markers are combined, and the sensitivity and the specificity are 98.5% and 98.3% respectively under the optimum cutoff value. The metabolic marker group can accurately diagnose and distinguish the coronary arterial atherosclerosis from the stable angina pectoris, and is high in sensitivity and specificity.

The invention relates to a pharmaceutical composition for treating stable angina and preparation method thereof. The pharmaceutical composition for treating stable angina is composed of salviae miltiorrhizae, flos carthami, radix astragali, hawthorn fruits, fruits of Chinese magnoliavine, pseudo-ginseng, longstamen onion bulb, snakegourd peel, fructus aurantii, red peony roots and musk. The forms of the pharmaceutical composition comprise a hard capsule form, a tablet form and a granule form. The pharmaceutical composition for treating stable angina has an exact curative effect, can lower the level of MDA and ET, and can well reduce damage caused by hypoxia.

Provided is the use of a Salvia Miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease, and particularly the use of the Salvia Miltiorrhiza composition in preparing drugs for secondary prevention of stable angina type coronary heart disease and the reduction of serious vascular events.

The invention discloses a metabolism marker for diagnosis and distinguishing of stable angina pectoris and acute coronary syndrome. The metabolism marker comprises one or more of 1,3-octadiene, sarcosine, phosphorylcholine, 2-hydroxylauric acid and tryptophan. When a single metabolism marker is used for diagnosis and distinguishing of stable angina pectoris patients and acute coronary syndrome patients, ROC area under the curve (AUC) is larger than 0.7, and clinical diagnostic significance is high; when several metabolism markers are combined to be used for diagnosis, AUC is further increased as the combination number increases and reaches the highest value 0.987 when all five metabolism markers are combined, and sensitivity and specificity are 96.9% and 97.6% respectively under the optimum cutoff value. The metabolism marker can be used for accurate diagnosis and distinguishing of stable angina pectoris and acute coronary syndrome and has high accuracy, sensitivity and specificity.

The invention relates to the technical field of medicines for treating cardiovascular and cerebtovascular diseases and discloses a medicine for treating coronary heart disease and a preparation method thereof. The medicine comprises sandalwood, pearl, Mastich, cassia bark, flower of Anchusa italic, cardamom, Crocus sativus, Operculina turpethum, tabasheer, aquilaria wood, phyllanthus emblica, Pterocarpus santalinus, coriander seed, Limonium gmelinii, purslane seed, amber, root of Centaurea cyanus L., musk, rose, silkworm cocoon, dracocephalum moldavica, Chinese usnea, berberis fruit and apple. Compared with the existing Uighur medicine Yangxindawayimixike honey paste, the medicine tablet provided by the invention has good effects of treating coronary heart disease angina and stable angina pectoris, has a small use amount, can be accurately quantified, is convenient for storage and carrying, and greatly reduces heavy metal content. Raw materials of the medicine are crushed into submicron powder and then are blended according to a certain ratio. The medicine is conducive to full absorption by a patient.

The present invention relates to compounds and compositions useful for inhibiting and / or reducing platelet deposition, adhesion and / or aggregation. The present invention further relates to a drug-eluting stent comprising said compounds and methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.

A panel of metabolic biomarkers for differential diagnosis of stable angina pectoris and acute coronary syndrome is published herein. The panel comprises one or more of the metabolic biomarkers, including malic acid, taurine, arachidonic acid, citramalic acid, methionine, pentadecanoic acid. Single use of the 6 differential metabolites provided clinically diagnostic value of SA vs. ACS with AUC>0.7. When combined, the more metabolites, the larger of AUC. The highest AUC of 0.987 was obtained when all of the six metabolites were combined to distinguish SA vs. ACS with sensitivity 96.8% and specificity 97.7% using optimal cut-off value. The metabolic biomarkers provided by the invention can be used for differential diagnosis of SA vs. ACS of high accuracy, sensitivity and specificity.

The invention discloses a metabolism marker group used for diagnosing and differentiating stable angina pectoris and acute coronary syndrome. The metabolism marker group comprises one or more selected from a group consisting of malic acid, taurine, arachidonic acid, citramalic acid, methionine and pentadecanoic acid. When an individual metabolism marker is used for diagnosing and differentiating patients with stable angina pectoris and patients with acute coronary syndrome, an area under a ROC curve (AUC) is greater than 0.7, the individual metabolism marker has clinical diagnosis significance; when metabolism markers are combined and used for diagnosis, AUC further increases with increase of the number of the combined metabolism markers; and AUC reaches a highest value of 0.987 when all the six metabolism markers are combined, and sensitivity and specificity are 96.8% and 97.7% respectively under the condition of an optimal cutoff value. The metabolism marker group provided by the invention can accurately diagnose and differentiate stable angina pectoris and acute coronary syndrome and has high sensitivity and good specificity.

Provided is the use of a Salvia Miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease, and particularly the use of the Salvia Miltiorrhiza composition in preparing drugs for secondary prevention of stable angina type coronary heart disease and the reduction of serious vascular events.

The invention discloses a Chinese medicinal composition for treating angina pectoris, and relates to the technical field of Chinese medicines. The Chinese medicinal composition is prepared from 10 to 40 weight parts of rosewood heart wood, 20 to 40 weight parts of sandalwood, 10 to 30 weight parts of the root of red-rooted salvia, 8 to 25 weight parts of angelica, 10 to 30 weight parts of szechuan lovage rhizome, 5 to 20 weight parts of ganoderma lucidum, 10 to 30 weight parts of leech and 5 to 24 weight parts of borneol. The Chinese medicinal composition has a special curative effect on the angina pectoris, and particularly has a remarkable curative effect on stable angina pectoris.

The invention belongs to the technical field of medicines and particularly relates to a traditional Chinese medicine for treating coronary heart disease stable angina pectoris complicated with hypertension and hyperlipidemia. The traditional Chinese medicine is prepared from the following raw materials in parts by weight: 8-16 parts of radix bupleuri, 6-14 parts of pericarpium citri reticulatae, 6-14 parts of pericarpium citri reticulatae viride, 6-14 parts of citrus chirocarpus, 6-14 parts of fructus citri, 6-14 parts of allium macrostemon, 6-14 parts of ginseng, 11-19 parts of codonopsis pilosula, 11-19 parts of radix pseudostellariae, 8-16 parts of bighead atractylodes rhizome, 5-13 parts of rhizoma atractylodis, 5-13 parts of pinellia ternate, 5-13 parts of rhizoma arisaematis, 16-24 parts of succus bambusae, 6-14 parts of trichosanthes kirilowii maxim, 5-13 parts of thunberg fritillary bulb, 5-13 parts of ligusticum wallichii, 5-13 parts of rhizoma corydalis, 5-13 parts of radix salviae miltiorrhizae, 5-13 parts of safflower carthamus, 1-5 parts of leech and 4-8 parts of liquorice. The traditional Chinese medicine has the advantages of high curative rate and high effective rate.